Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1371Observational 29Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

venetoclax 3fludarabine phosphate 3fludarabine 3navitoclax 2ibrutinib 2brexucabtagene autoleucel 2axicabtagene ciloleucel 2asparaginase erwinia chrysanthemi recombinant 2Cyclophosphamide 2zanubrutinib 1tisagenlecleucel 1tipifarnib 1tafasitamab 1sugemalimab 1selinexor 1plerixafor 1pirtobrutinib 1nilotinib 1midostaurin 1loncastuximab tesirine 1idelalisib 1glucarpidase 1eryaspase 1ceritinib 1Whole-Body Irradiation 1Tacrolimus 1Rituximab 1Proton Pump Inhibitors 1Mycophenolic Acid 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Rituximab × Lymphoid × Clear all
NCT02136511 2014-10-28

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Gilead Sciences

Approved for marketing
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡